Insider trade

CEO sold ~$64K of UTHR shares in the open market

Traded Mar 25, 2026 · Filed Mar 27, 2026

Why it stands out

The CEO of United Therapeutics sold $64K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CEO$25K–$100KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$64,436

Shares × reported transaction price

Timing vs results

28 days after results of Feb 25, 2026, 42 days before results of May 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+7.0%	+3.9%	+3.1%
30 days	+8.4%	+12.8%	−4.3%
90 days	+3.9%	+15.8%	−11.9%
180 days	−6.4%	+21.1%	−27.5%

Past results only. Not a forecast.

This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

Filed 6mo ago

Traded Apr 23 · filed 2 days later

Derivative exercise or conversion — not an open-market buy.

Scheduled in advanceFiled 6mo ago

Scheduled in advanceFiled 6mo ago